Imagene

Imagene was founded with a clear mission to leverage AI to profile, in real time, a broad range of biomarkers from biopsy images. By doing so, the company aims to overcome economical, logistical, and technological barriers to reach the full potential of precision medicine for all cancer patients. Imagene's technology classifies patterns that cannot be seen by the human eye, evolving genomics, proteomics, and spatial insights, resulting in a fast and accurate molecular profiling. The company's technology also enables better stratification of patients for clinical trials and the discovery of novel targets for new drugs. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide. It was selected for The Marker's Most Promising Start-Ups for 2022, and named Oncology Innovation of the Year by the BioTech Breakthrough Awards. Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is working to revolutionize molecular screening for both clinical practice and research.

Imagene has raised $44.5M in total funding across 3 rounds. The company is currently at the B stage. Key investors include Larry Ellison, Aguras, Eyal Gura.

Imagene was founded in 2020 by Dean Bitan (Co-founder & CEO), Shahar Porat (Co-founder & CTO), Jonathan Zalach (Co-founder & Chief Data Scientist).

Imagene operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Artificial Intelligence, Deep Learning, Computer Vision. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients, Providers.

Imagene is based in Yitzhak Sadeh St 17, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.